Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1131 related articles for article (PubMed ID: 11156256)

  • 1. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model.
    Mohammad RM; Wall NR; Dutcher JA; Al-Katib AM
    Clin Cancer Res; 2000 Dec; 6(12):4950-6. PubMed ID: 11156256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1.
    Mohammad RM; Goustin AS; Aboukameel A; Chen B; Banerjee S; Wang G; Nikolovska-Coleska Z; Wang S; Al-Katib A
    Clin Cancer Res; 2007 Apr; 13(7):2226-35. PubMed ID: 17404107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts.
    Al-Katib AM; Smith MR; Kamanda WS; Pettit GR; Hamdan M; Mohamed AN; Chelladurai B; Mohammad RM
    Clin Cancer Res; 1998 May; 4(5):1305-14. PubMed ID: 9607591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genistein sensitizes diffuse large cell lymphoma to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy.
    Mohammad RM; Al-Katib A; Aboukameel A; Doerge DR; Sarkar F; Kucuk O
    Mol Cancer Ther; 2003 Dec; 2(12):1361-8. PubMed ID: 14707277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1.
    Mohammad RM; Varterasian ML; Almatchy VP; Hannoudi GN; Pettit GR; Al-Katib A
    Clin Cancer Res; 1998 May; 4(5):1337-43. PubMed ID: 9607595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma.
    Al-Katib AM; Aboukameel A; Mohammad R; Bissery MC; Zuany-Amorim C
    Clin Cancer Res; 2009 Jun; 15(12):4038-45. PubMed ID: 19509168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China--a multi-center randomized trail].
    Lin TY; Zhang HY; Huang Y; Guan ZZ; Shen T; Shi YK; Zhu J; Ke XY; Wang HQ; Shen ZX; Yu SY; Liu T; Shi XL
    Ai Zheng; 2005 Dec; 24(12):1421-6. PubMed ID: 16351785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I and correlative study of combination bryostatin 1 and vincristine in relapsed B-cell malignancies.
    Dowlati A; Lazarus HM; Hartman P; Jacobberger JW; Whitacre C; Gerson SL; Ksenich P; Cooper BW; Frisa PS; Gottlieb M; Murgo AJ; Remick SC
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5929-35. PubMed ID: 14676117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].
    Wu HJ; Zhang QY; Chen DF; Guan XJ; Zhang BL; Ma J
    Ai Zheng; 2005 Dec; 24(12):1498-502. PubMed ID: 16351800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential treatment of human chronic lymphocytic leukemia with bryostatin 1 followed by 2-chlorodeoxyadenosine: preclinical studies.
    Mohammad RM; Katato K; Almatchy VP; Wall N; Liu KZ; Schultz CP; Mantsch HH; Varterasian M; al-Katib AM
    Clin Cancer Res; 1998 Feb; 4(2):445-53. PubMed ID: 9516935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination chemotherapy and rituximab.
    Czuczman MS
    Anticancer Drugs; 2001 Jun; 12 Suppl 2():S15-9. PubMed ID: 11508932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow.
    Koutcher JA; Motwani M; Zakian KL; Li XK; Matei C; Dyke JP; Ballon D; Yoo HH; Schwartz GK
    Clin Cancer Res; 2000 Apr; 6(4):1498-507. PubMed ID: 10778982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long term remission of Sj√∂gren's syndrome associated aggressive B cell non-Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone).
    Voulgarelis M; Giannouli S; Tzioufas AG; Moutsopoulos HM
    Ann Rheum Dis; 2006 Aug; 65(8):1033-7. PubMed ID: 16322082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of cIAP-1 by novel antitubulin agents when combined with bryostatin 1 results in increased apoptosis in the human early pre-B acute lymphoblastic leukemia cell line Reh.
    Wall NR; Mohammad RM; Nabha SM; Pettit GR; Al-Katib AM
    Biochem Biophys Res Commun; 1999 Dec; 266(1):76-80. PubMed ID: 10581168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential treatment of a resistant chronic lymphocytic leukemia patient with bryostatin 1 followed by 2-chlorodeoxyadenosine: case report.
    Ahmad I; Al-Katib AM; Beck FW; Mohammad RM
    Clin Cancer Res; 2000 Apr; 6(4):1328-32. PubMed ID: 10778958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic interaction of selected marine animal anticancer drugs against human diffuse large cell lymphoma.
    Mohammad RM; Pettit GR; Almatchy VP; Wall N; Varterasian M; Al-Katib A
    Anticancer Drugs; 1998 Feb; 9(2):149-56. PubMed ID: 9510501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(-)-gossypol] against diffuse large cell lymphoma.
    Mohammad RM; Wang S; Aboukameel A; Chen B; Wu X; Chen J; Al-Katib A
    Mol Cancer Ther; 2005 Jan; 4(1):13-21. PubMed ID: 15657349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized study comparing doxorubicin, cyclophosphamide, vincristine, methotrexate with leucovorin rescue, and cytarabine (ACOMLA) with cyclophosphamide, doxorubicin, vincristine, prednisone, and bleomycin (CHOP-B) in the treatment of diffuse histiocytic lymphoma.
    Newcomer LN; Cadman EC; Nerenberg MI; Chen M; Bertino JR; Farber LR; Prosnitz LR
    Cancer Treat Rep; 1982 Jun; 66(6):1279-84. PubMed ID: 6177407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A case of diffuse large cell lymphoma treated with combination chemotherapy of CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) and BEMP (bleomycin, etoposide, mitoxantrone, procarbazine) with complete remission].
    Itoh T; Sakata Y; Suzuki H; Sugimoto N; Sohma N; Kishibe T; Higuchi S; Seino Y
    Gan To Kagaku Ryoho; 1992 Feb; 19(2):241-4. PubMed ID: 1371049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.